Tumor immunotherapy has become a new hotspot for cancer treatment. Various immunotherapies, such as immune checkpoint inhibitors, oncolytic viruses (OVs), cytokines, and cancer vaccines, have been used to treat tumors. They operate through different mechanisms, along with certain toxicities and side effects. Understanding the mechanisms by which immunotherapy modulates the immune system is essential for improving the efficacy and managing these adverse effects. This article discusses various currently approved cancer immunotherapy mechanisms and related agents approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency. We also review the latest progress in immune drugs approved by the National Medical Products Administration, including monoclonal antibodies, cytokines, OVs, and chimeric antigen receptor-T cell therapy, to help understand the clinical application of tumor immunotherapy.

01 Jan 2024·Bioactive Materials

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Review

Author: Yin, Dengke ; Xiao, Chunsheng ; Liu, Wanguo ; Liu, Hanmeng ; Shen, Wei ; Yang, Zexin

Traditional cancer therapy methods, especially those directed against specific intracellular targets or signaling pathways, are not powerful enough to overcome tumor heterogeneity and therapeutic resistance. Oncolytic peptides that can induce membrane lysis-mediated cancer cell death and subsequent anticancer immune responses, has provided a new paradigm for cancer therapy. However, the clinical application of oncolytic peptides is always limited by some factors such as unsatisfactory bio-distribution, poor stability, and off-target toxicity. To overcome these limitations, oncolytic polymers stand out as prospective therapeutic materials owing to their high stability, chemical versatility, and scalable production capacity, which has the potential to drive a revolution in cancer treatment. This review provides an overview of the mechanism and structure-activity relationship of oncolytic peptides. Then the oncolytic peptides-mediated combination therapy and the nano-delivery strategies for oncolytic peptides are summarized. Emphatically, the current research progress of oncolytic polymers has been highlighted. Lastly, the challenges and prospects in the development of oncolytic polymers are discussed.

30 Aug 2023·Annals of translational medicine

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?

Communications

Author: Wongariyapak, Amarin ; Roulstone, Victoria ; Melcher, Alan A ; Harrington, Kevin J ; Pedersen, Malin

100 Deals associated with Oncolytic viruses(EpicentRx, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	-	EpicentRx, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASGCT2011	Not Applicable	Triple Negative Breast Cancer	-	Oncolytic Viruses	pjcxbhbzvk(ybjwbegbtv) = wdphqigtec xjmceklpwm (sobhkvcbyt ) View more	-	01 May 2011
				Oncolytic Viruses	bgykcscaar(hgaodwredu) = oddgheyklh tbuiwetzzs (agbxkmfxzv )
ASGCT2009	Not Applicable	Sickle Cell Trait	-	Oncolytic Viruses	(baulnxipyu) = cgofkskini tltkqhilnl (fznrxzirkx )	-	01 May 2009
				Oncolytic viruses	(baulnxipyu) = fswjgpkbbn tltkqhilnl (fznrxzirkx )
ASGCT2004	Not Applicable	Toxicity	-	Oncolytic Viruses	kvlcpbravh(tutwadvhxt) = izculdfiey qvpglsqlrk (winmxvhdde )	Positive	01 May 2004

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Oncolytic viruses(EpicentRx, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation